Generium and Exacte Labs conduct clinical trials of COVID-vaccine
Pharmaceutical Company GENERIUM in cooperation with Research Center Exacte Labs has started Phase II-III clinical trials of GNR-099 combined nasal vector vaccine against coronavirus.
A double-blind, randomized clinical trial of the drug's safety and immunogenicity will involve 1,320 volunteers, according to the state registry of clinical trial approvals.
During the study, the immunogenicity and safety of the vaccine will be compared with those of the drug Gam-COVID-Vac. The study is scheduled to run through December 31, 2023.